RSS

Biogen

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Biogen and AbbVie have announced the voluntary global withdrawal of Zinbryta (daclizumab) — a treatment for relapsing multiple sclerosis (MS) — in the best interests of patient safety. more

News

Here, Michael Merges, Catalent Biologics, and Brian Fahie, Biogen, discuss the growing need for partners who can provide niche technologies to accelerate development projects. more

, Opinion

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion, recommending that biosimilar Imraldi be granted marketing authorisation. more

News

The CHMP has given a positive opinion recommending that Biogen’s treatment for patients with spinal muscular atrophy (SMA), SPINRAZA (nusinersen), be granted marketing authorisation. more

News

According to business intelligence provider GBI Research, pharmaceuticals company Roche will be the biggest mover in the neurodegenerative drugs space over the next five years. more

News

A clinical trial of a new drug shows promising results for those suffering early-stage Alzheimer’s more

News

Pfizer, AstraZeneca, Merck and other Big Pharma companies have signed up to a consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s more

News

Calchan has announced an established management team, led by Brenda Reynolds, CEO, which has a successful track record of building UK-based companies, creating value for investors and commercialisng IP. more

News